- Home
- AMRN vs MITT Comparison
AMRN vs MITT Comparison
Compare AMRN & MITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- MITT
- Stock Information
- Founded
- AMRN 1989
- MITT 2011
- Country
- AMRN Ireland
- MITT United States
- Employees
- AMRN N/A
- MITT N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- MITT Real Estate Investment Trusts
- Sector
- AMRN Health Care
- MITT Real Estate
- Exchange
- AMRN Nasdaq
- MITT Nasdaq
- Market Cap
- AMRN 216.0M
- MITT 178.5M
- IPO Year
- AMRN 1993
- MITT 2011
- Fundamental
- Price
- AMRN $10.41
- MITT $6.82
- Analyst Decision
- AMRN Sell
- MITT Buy
- Analyst Count
- AMRN 2
- MITT 5
- Target Price
- AMRN $7.00
- MITT $8.30
- AVG Volume (30 Days)
- AMRN 116.9K
- MITT 230.5K
- Earning Date
- AMRN 05-07-2025
- MITT 05-06-2025
- Dividend Yield
- AMRN N/A
- MITT 11.75%
- EPS Growth
- AMRN N/A
- MITT N/A
- EPS
- AMRN N/A
- MITT 1.23
- Revenue
- AMRN $214,112,000.00
- MITT $87,547,000.00
- Revenue This Year
- AMRN N/A
- MITT N/A
- Revenue Next Year
- AMRN $0.89
- MITT $7.93
- P/E Ratio
- AMRN N/A
- MITT $5.54
- Revenue Growth
- AMRN N/A
- MITT 37.53
- 52 Week Low
- AMRN $7.00
- MITT $5.63
- 52 Week High
- AMRN $20.60
- MITT $7.95
- Technical
- Relative Strength Index (RSI)
- AMRN 53.84
- MITT 55.49
- Support Level
- AMRN $9.44
- MITT $6.33
- Resistance Level
- AMRN $11.44
- MITT $6.69
- Average True Range (ATR)
- AMRN 0.85
- MITT 0.20
- MACD
- AMRN -0.01
- MITT 0.09
- Stochastic Oscillator
- AMRN 47.09
- MITT 86.42
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About MITT AG Mortgage Investment Trust Inc.
AG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. It also focuses on investing in residential mortgage-backed securities (RMBS) issued or guaranteed by a government-sponsored enterprise.